Peter L Choyke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7701438/publications.pdf

Version: 2024-02-01

161 papers 18,214 citations

56 h-index 132 g-index

164 all docs

 $\begin{array}{c} 164 \\ \\ \text{docs citations} \end{array}$

164 times ranked 16156 citing authors

#	Article	IF	CITATIONS
1	Translating a radiolabeled imaging agent to the clinic. Advanced Drug Delivery Reviews, 2022, 181, 114086.	6.6	6
2	CD29 targeted near-infrared photoimmunotherapy (NIR-PIT) in the treatment of a pigmented melanoma model. Oncolmmunology, 2022, 11, 2019922.	2.1	13
3	Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapy. Cancer Immunology, Immunotherapy, 2022, 71, 1877-1887.	2.0	9
4	Advances in Preclinical PET. Seminars in Nuclear Medicine, 2022, 52, 382-402.	2. 5	8
5	Endoscopic Applications of Near-Infrared Photoimmunotherapy (NIR-PIT) in Cancers of the Digestive and Respiratory Tracts. Biomedicines, 2022, 10, 846.	1.4	3
6	Advancing Research on Medical Image Perception by Strengthening Multidisciplinary Collaboration. JNCI Cancer Spectrum, 2022, 6, .	1.4	2
7	PET of Fibroblast-Activation Protein for Cancer Staging: What We Know and What We Need to Learn. Radiology, 2022, , 220742.	3.6	1
8	Near-Infrared Photoimmunotherapy (NIR-PIT) in Urologic Cancers. Cancers, 2022, 14, 2996.	1.7	9
9	Comparison of the Effectiveness of IgG Antibody versus F(ab′) ₂ Antibody Fragment in CTLA4-Targeted Near-Infrared Photoimmunotherapy. Molecular Pharmaceutics, 2022, 19, 3600-3611.	2.3	1
10	Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 143-151.	3.3	25
11	Novel PET imaging methods for prostate cancer. World Journal of Urology, 2021, 39, 687-699.	1.2	12
12	Deep Learning Based Staging of Bone Lesions From Computed Tomography Scans. IEEE Access, 2021, 9, 87531-87542.	2.6	12
13	Local Depletion of Immune Checkpoint Ligand CTLA4 Expressing Cells in Tumor Beds Enhances Antitumor Host Immunity. Advanced Therapeutics, 2021, 4, 2000269.	1.6	27
14	Near infrared photoimmunotherapy of cancer; possible clinical applications. Nanophotonics, 2021, 10, 3135-3151.	2.9	19
15	Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy. Cancers, 2021, 13, 2535.	1.7	47
16	Near-infrared photoimmunotherapy targeting human-EGFR in a mouse tumor model simulating current and future clinical trials. EBioMedicine, 2021, 67, 103345.	2.7	21
17	Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens. Radiology, 2021, 299, 613-623.	3.6	11
18	68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas $\hat{a} \in \mathbb{C}$ Imaging analysis and histological validation. Radiotherapy and Oncology, 2021, 160, 192-201.	0.3	40

#	Article	IF	CITATIONS
19	Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models. Molecular Cancer Therapeutics, 2021, 20, 2262-2273.	1.9	20
20	Future applications of and prospects for near-IR photoimmunotherapy: benefits and differences compared with photodynamic and photothermal therapy. Immunotherapy, 2021, 13, 1305-1307.	1.0	2
21	Rapid Depletion of Intratumoral Regulatory T Cells Induces Synchronized CD8 T- and NK-cell Activation and IFNÎ ³ -Dependent Tumor Vessel Regression. Cancer Research, 2021, 81, 3092-3104.	0.4	20
22	Apical periurethral transition zone lesions: MRI and histology findings. Abdominal Radiology, 2020, 45, 3258-3264.	1.0	0
23	Near-Infrared Photoimmunotherapy: Photoactivatable Antibody–Drug Conjugates (ADCs). Bioconjugate Chemistry, 2020, 31, 28-36.	1.8	45
24	Can Molecular Imaging Measure T-cell Activation?. Cancer Research, 2020, 80, 2975-2976.	0.4	5
25	Prospective Evaluation of ¹⁸ F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI. American Journal of Roentgenology, 2020, 215, 652-659.	1.0	22
26	Near-Infrared Photoimmunotherapy Combined with CTLA4 Checkpoint Blockade in Syngeneic Mouse Cancer Models. Vaccines, 2020, 8, 528.	2.1	23
27	The Bosniak Classification Gets Even Better. Radiology, 2020, 297, 606-607.	3.6	4
28	Increased Immunogenicity of a Minimally Immunogenic Tumor after Cancer-Targeting Near Infrared Photoimmunotherapy. Cancers, 2020, 12, 3747.	1.7	23
29	A Grading System for Extraprostatic Extension of Prostate Cancer That We Can All Agree Upon?. Radiology Imaging Cancer, 2020, 2, e190088.	0.7	3
30	MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. New England Journal of Medicine, 2020, 382, 917-928.	13.9	515
31	Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of ¹⁸ F-DCFPyL PET/CT with Comparison to Multiparametric MRI. Radiology, 2020, 296, 564-572.	3.6	24
32	Combined CD44- and CD25-Targeted Near-Infrared Photoimmunotherapy Selectively Kills Cancer and Regulatory T Cells in Syngeneic Mouse Cancer Models. Cancer Immunology Research, 2020, 8, 345-355.	1.6	48
33	Impact of bowel preparation with Fleet's™ enema on prostate MRI quality. Abdominal Radiology, 2020, 45, 4252-4259.	1.0	26
34	Mutation Profiles of Urothelial Cancer: Will Genomics Change Radiology or Vice Versa?. Radiology, 2020, 295, 581-582.	3.6	0
35	In Vitro Performance of Published Glypican 3-Targeting Peptides TJ12P1 and L5 Indicates Lack of Specificity and Potency. Cancer Biotherapy and Radiopharmaceuticals, 2019, 34, 498-503.	0.7	5
36	Near-Infrared Photoimmunotherapy of Cancer. Accounts of Chemical Research, 2019, 52, 2332-2339.	7.6	286

3

#	Article	IF	Citations
37	The Effect of Antibody Fragments on CD25 Targeted Regulatory T Cell Near-Infrared Photoimmunotherapy. Bioconjugate Chemistry, 2019, 30, 2624-2633.	1.8	35
38	A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI. Radiology, 2019, 290, 709-719.	3.6	140
39	Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors. Cancer Immunology Research, 2019, 7, 401-413.	1.6	99
40	New Targets for PET Molecular Imaging of Prostate Cancer. Seminars in Nuclear Medicine, 2019, 49, 326-336.	2.5	21
41	A multiparametric magnetic resonance imaging-based virtual reality surgical navigation tool for robotic-assisted radical prostatectomy. Turkish Journal of Urology, 2019, 45, 357-365.	1.3	18
42	Prospective comparison of Plâ€RADS version 2 and qualitative inâ€house categorization system in detection of prostate cancer. Journal of Magnetic Resonance Imaging, 2018, 48, 1326-1335.	1.9	18
43	Computer-aided diagnosis prior to conventional interpretation of prostate mpMRI: an international multi-reader study. European Radiology, 2018, 28, 4407-4417.	2.3	68
44	MRI-Guided Robotically Assisted Focal Laser Ablation of the Prostate Using Canine Cadavers. IEEE Transactions on Biomedical Engineering, 2018, 65, 1434-1442.	2.5	36
45	Future Perspectives and Challenges of Prostate MR Imaging. Radiologic Clinics of North America, 2018, 56, 327-337.	0.9	11
46	What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. Radiology, 2018, 286, 186-195.	3.6	188
47	Ruling out clinically significant prostate cancer with negative multi-parametric MRI. International Urology and Nephrology, 2018, 50, 7-12.	0.6	19
48	Photoinduced Ligand Release from a Silicon Phthalocyanine Dye Conjugated with Monoclonal Antibodies: A Mechanism of Cancer Cell Cytotoxicity after Near-Infrared Photoimmunotherapy. ACS Central Science, 2018, 4, 1559-1569.	5.3	171
49	MRI Robot for Prostate Focal Laser Ablation: An Ex Vivo Study in Human Prostate. Journal of Imaging, 2018, 4, 140.	1.7	8
50	Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy. Diagnostic and Interventional Radiology, 2018, 24, 46-53.	0.7	21
51	Endoscopic near infrared photoimmunotherapy using a fiber optic diffuser for peritoneal dissemination of gastric cancer. Cancer Science, 2018, 109, 1902-1908.	1.7	37
52	Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer. Radiology, 2018, 288, 485-491.	3.6	53
53	Quantitative MRI or Machine Learning for Prostate MRI: Which Should You Use?. Radiology, 2018, 289, 138-139.	3.6	11
54	Detection of prostate cancer in multiparametric MRI using random forest with instance weighting. Journal of Medical Imaging, 2017, 4, 024506.	0.8	33

#	Article	IF	CITATIONS
55	Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody. Molecular Cancer Research, 2017, 15, 1153-1162.	1.5	69
56	The Current State of MR Imaging–targeted Biopsy Techniques for Detection of Prostate Cancer. Radiology, 2017, 285, 343-356.	3.6	88
57	Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti–CD44-Based NIR-PIT. Molecular Cancer Research, 2017, 15, 1667-1677.	1.5	64
58	Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2. Radiology, 2017, 285, 859-869.	3.6	126
59	Comparison of planar, PET and well-counter measurements of total tumor radioactivity in a mouse xenograft model. Nuclear Medicine and Biology, 2017, 53, 29-36.	0.3	2
60	18F-DCFBC Prostate-Specific Membrane Antigen–Targeted PET/CT Imaging in Localized Prostate Cancer. Clinical Nuclear Medicine, 2017, 42, 735-740.	0.7	23
61	Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges. Radiology, 2017, 285, 728-743.	3.6	38
62	Hereditary Renal Tumor Syndromes: Update on Diagnosis and Management. Seminars in Ultrasound, CT and MRI, 2017, 38, 59-71.	0.7	16
63	Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer. Journal of Urology, 2017, 197, 640-646.	0.2	90
64	Robotic System for MRI-Guided Focal Laser Ablation in the Prostate. IEEE/ASME Transactions on Mechatronics, 2017, 22, 107-114.	3.7	39
65	Prostate Cancer: A Correlative Study of Multiparametric MR Imaging and Digital Histopathology. Radiology, 2017, 285, 147-156.	3.6	33
66	Quantitative Image Quality Comparison of Reduced- and Standard-Dose Dual-Energy Multiphase Chest, Abdomen, and Pelvis CT. Tomography, 2017, 3, 114-122.	0.8	10
67	Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. Oncotarget, 2017, 8, 10425-10436.	0.8	179
68	Dynamic changes in the cell membrane on three dimensional low coherent quantitative phase microscopy (3D LC-QPM) after treatment with the near infrared photoimmunotherapy. Oncotarget, 2017, 8, 104295-104302.	0.8	24
69	Multiparametric Magnetic Resonance Imaging for Active Surveillance of Prostate Cancer. Balkan Medical Journal, 2017, 34, 388-396.	0.3	5
70	Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e235-e245.	1.8	26
71	Comparative effectiveness of light emitting diodes (LEDs) and Lasers in near infrared photoimmunotherapy. Oncotarget, 2016, 7, 14324-14335.	0.8	42
72	Robot for Magnetic Resonance Imaging Guided Focal Prostate Laser Ablation 1. Journal of Medical Devices, Transactions of the ASME, 2016, 10, .	0.4	4

#	Article	IF	Citations
73	Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions. Journal of the National Cancer Institute, 2016, 108, djw039.	3.0	68
74	Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection. Journal of Urology, 2016, 196, 690-696.	0.2	116
75	Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. Ca-A Cancer Journal for Clinicians, 2016, 66, 326-336.	157.7	128
76	Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. Science Translational Medicine, 2016, 8, 352ra110.	5.8	163
77	Advancement of MR and PET/MR in Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 536-543.	2.5	21
78	Do Radiologists Have Stage Fright? Tumor Staging and How We Can Add Value to the Care of Patients with Cancer. Radiology, 2016, 278, 11-12.	3.6	15
79	PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2. European Urology, 2016, 69, 16-40.	0.9	2,290
80	Near-infrared photoimmunotherapy with galactosyl serum albumin in a model of diffuse peritoneal disseminated ovarian cancer. Oncotarget, 2016, 7, 79408-79416.	0.8	17
81	MRIâ€based prostate volumeâ€adjusted prostateâ€specific antigen in the diagnosis of prostate cancer. Journal of Magnetic Resonance Imaging, 2015, 42, 1733-1739.	1.9	23
82	Posterior subcapsular prostate cancer: identification with mpMRI and MRI/TRUS fusion-guided biopsy. Abdominal Imaging, 2015, 40, 2557-2565.	2.0	34
83	Clinical Implications of a Multiparametric Magnetic Resonance Imaging Based Nomogram Applied to Prostate Cancer Active Surveillance. Journal of Urology, 2015, 193, 1943-1949.	0.2	60
84	Near infrared photoimmunotherapy for lung metastases. Cancer Letters, 2015, 365, 112-121.	3.2	62
85	Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. Radiology, 2015, 277, 741-750.	3.6	296
86	Comparison of MR/Ultrasound Fusion–Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 390.	3.8	1,267
87	⁸⁹ Zr-Oxine Complex PET Cell Imaging in Monitoring Cell-based Therapies. Radiology, 2015, 275, 490-500.	3.6	121
88	Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET. Current Oncology Reports, 2015, 17, 56.	1.8	13
89	Multiparametric magnetic resonance imaging-transrectal ultrasound fusion–assisted biopsy for the diagnosis of local recurrence after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 425.e1-425.e6.	0.8	32
90	Multiparametric magnetic resonance imaging (<scp>MRI</scp>) and subsequent <scp>MRI</scp> /ultrasonography fusionâ€guided biopsy increase the detection of anteriorly located prostate cancers. BJU International, 2014, 114, E43-E49.	1.3	103

#	Article	IF	Citations
91	Localized Prostate Cancer Detection with ^{18 < /sup>F FACBC PET/CT: Comparison with MR Imaging and Histopathologic Analysis. Radiology, 2014, 270, 849-856.}	3.6	141
92	Anti-1-Amino-3- ¹⁸ F-Fluorocyclobutane-1-Carboxylic Acid: Physiologic Uptake Patterns, Incidental Findings, and Variants That May Simulate Disease. Journal of Nuclear Medicine, 2014, 55, 1986-1992.	2.8	138
93	Nanoparticles: Take Only Pictures, Leave Only Footprints. Science Translational Medicine, 2014, 6, 260fs44.	5.8	5
94	Assessment of Tumor Growth in Pancreatic Neuroendocrine Tumors in von Hippel Lindau Syndrome. Journal of the American College of Surgeons, 2014, 218, 163-169.	0.2	32
95	Current Ability of Multiparametric Prostate Magnetic Resonance Imaging and Targeted Biopsy to Improve the Detection of Prostate Cancer. Urology Practice, 2014, 1, 13-21.	0.2	7
96	Cancer Drug Delivery: Considerations in the Rational Design of Nanosized Bioconjugates. Bioconjugate Chemistry, 2014, 25, 2093-2100.	1.8	68
97	Photoimmunotherapy: Comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor. Molecular Oncology, 2014, 8, 620-632.	2.1	95
98	Markedly Enhanced Permeability and Retention Effects Induced by Photo-immunotherapy of Tumors. ACS Nano, 2013, 7, 717-724.	7.3	237
99	Performance characteristics of a positron projection imager for mouse whole-body imaging. Nuclear Medicine and Biology, 2013, 40, 321-330.	0.3	4
100	Meeting the challenges of PET-based molecular imaging in cancer. Expert Review of Molecular Diagnostics, 2013, 13, 671-680.	1.5	1
101	Fully Automated Prostate Segmentation on MRI: Comparison With Manual Segmentation Methods and Specimen Volumes. American Journal of Roentgenology, 2013, 201, W720-W729.	1.0	52
102	Science to Practice: Imaging Cancer-associated Fibroblastsâ€"No Innocent Bystanders. Radiology, 2013, 268, 617-618.	3.6	1
103	Near-infrared Theranostic Photoimmunotherapy (PIT): Repeated Exposure of Light Enhances the Effect of Immunoconjugate. Bioconjugate Chemistry, 2012, 23, 604-609.	1.8	136
104	Very distal apical prostate tumours: identification on multiparametric MRI at 3 Tesla. BJU International, 2012, 110, E694-700.	1.3	52
105	Correlation of Magnetic Resonance Imaging Tumor Volume with Histopathology. Journal of Urology, 2012, 188, 1157-1163.	0.2	188
106	ESUR prostate MR guidelines 2012. European Radiology, 2012, 22, 746-757.	2.3	2,176
107	Biologically Optimized Nanosized Molecules and Particles: More than Just Size. Bioconjugate Chemistry, 2011, 22, 993-1000.	1.8	149
108	Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nature Medicine, 2011, 17, 1685-1691.	15.2	851

#	Article	IF	CITATIONS
109	An MRI-Compatible Robotic System With Hybrid Tracking for MRI-Guided Prostate Intervention. IEEE Transactions on Biomedical Engineering, 2011, 58, 3049-3060.	2.5	85
110	Science to Practice: Angiogenic Marker Expression during Tumor Growthâ€"Can Targeted US Microbubbles Help Monitor Molecular Changes in the Microvasculature?. Radiology, 2011, 258, 655-656.	3.6	2
111	Science to Practice: Pilot Study of FPPRGD2 for Imaging α _v β ₃ Integrin—How Integral Are Integrins?. Radiology, 2011, 260, 1-2.	3. 6	13
112	Toxicity of Organic Fluorophores Used in Molecular Imaging: Literature Review. Molecular Imaging, 2009, 8, 7290.2009.00031.	0.7	358
113	Can Imaging Gene Expression in Human Mesenchymal Stem Cells be Successful in Large Animals?. Radiology, 2009, 252, 1-3.	3 . 6	5
114	Commentary on "Computed Tomography in the Diagnosis of Adrenal Disease―and "Nonfunctioning Adrenal Masses: Incidental Discovery on Computed Tomography― American Journal of Roentgenology, 2009, 192, 568-570.	1.0	3
115	Nanoparticles in sentinel lymph node mapping. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2009, 1, 610-623.	3.3	51
116	Radiologic evaluation of hematuria: guidelines from the American College of Radiology's appropriateness criteria. American Family Physician, 2008, 78, 347-52.	0.1	27
117	Is It Possible to Quantify Fluorescence during Optical Endoscopy?. Radiology, 2007, 245, 307-308.	3.6	3
118	The emerging role of molecular imaging and targeted therapeutics in peritoneal carcinomatosis. Expert Opinion on Drug Delivery, 2007, 4, 389-402.	2.4	17
119	MRI of tumor angiogenesis. Journal of Magnetic Resonance Imaging, 2007, 26, 235-249.	1.9	253
120	ACR Appropriateness Criteria $\hat{A}^{\text{@}}$ on Incidentally Discovered Adrenal Mass. Journal of the American College of Radiology, 2006, 3, 498-504.	0.9	54
121	Contrast Agents for Imaging Tumor Angiogenesis: Is Bigger Better?. Radiology, 2005, 235, 1-2.	3.6	27
122	System for prostate brachytherapy and biopsy in a standard 1.5 T MRI scanner. Magnetic Resonance in Medicine, 2004, 52, 683-687.	1.9	123
123	Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. Journal of Magnetic Resonance Imaging, 2003, 17, 509-520.	1.9	401
124	Imaging of hereditary renal cancer. Radiologic Clinics of North America, 2003, 41, 1037-1051.	0.9	30
125	Hereditary Renal Cancers. Radiology, 2003, 226, 33-46.	3.6	210
126	Special Techniques for Imaging Blood Flow to Tumors. Cancer Journal (Sudbury, Mass), 2002, 8, 109-118.	1.0	19

#	Article	IF	Citations
127	A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma., 2002, 94, 2333.		1
128	PARENCHYMAL SPARING SURGERY IN A PATIENT WITH MULTIPLE BILATERAL PAPILLARY RENAL CANCER. Journal of Urology, 2001, 165, 1623-1624.	0.2	8
129	PARENCHYMAL SPARING SURGERY IN PATIENTS WITH HEREDITARY RENAL CELL CARCINOMA: 10-YEAR EXPERIENCE. Journal of Urology, 2001, 165, 777-781.	0.2	198
130	A Prospective Analysis of Plasma Endostatin Levels in Colorectal Cancer Patients With Liver Metastases. Annals of Surgical Oncology, 2001, 8, 741-745.	0.7	56
131	Preferential arterial imaging using gated thick-slice gadolinium-enhanced phase-contrast acquisition in peripheral MRA. Journal of Magnetic Resonance Imaging, 2001, 13, 714-721.	1.9	5
132	A Phase I study of infusional vinblastine in combination with the p-glycoprotein antagonist PSC 833 (valspodar). Cancer, 2001, 92, 1577-1590.	2.0	76
133	Merging of intersecting triangulations for finite element modeling. Journal of Biomechanics, 2001, 34, 815-819.	0.9	67
134	Prostate Cancer. American Journal of Roentgenology, 2001, 176, 17-22.	1.0	35
135	A Phase I study of infusional vinblastine in combination with the p-glycoprotein antagonist PSC 833 (valspodar)., 2001, 92, 1577.		1
136	Imaging of urea using chemical exchange-dependent saturation transfer at 1.5T. Journal of Magnetic Resonance Imaging, 2000, $12,745-748$.	1.9	58
137	Bolus-chase peripheral 3D MRA using a dual-rate contrast media injection. Journal of Magnetic Resonance Imaging, 2000, 12, 769-775.	1.9	19
138	Ferumoxide-enhanced MRI in patients with colorectal cancer and rising CEA: surgical correlation in early recurrence. Magnetic Resonance Imaging, 2000, 18, 305-309.	1.0	20
139	Case 18: Adrenocorticotropic Hormone-dependent Cushing Syndrome. Radiology, 2000, 214, 195-198.	3.6	7
140	A PHASE 2 STUDY OF RADIO FREQUENCY INTERSTITIAL TISSUE ABLATION OF LOCALIZED RENAL TUMORS. Journal of Urology, 2000, 163, 1424-1427.	0.2	87
141	Automated bolus chase peripheral MR angiography: Initial practical experiences and future directions of this work-in-progress. Journal of Magnetic Resonance Imaging, 1999, 10, 376-388.	1.9	103
142	Screening for Wilms tumor in children with Beckwith-Wiedemann syndrome or idiopathic hemihypertrophy., 1999, 32, 196-200.		138
143	RENAL CANCER IN FAMILIES WITH HEREDITARY RENAL CANCER: PROSPECTIVE ANALYSIS OF A TUMOR SIZE THRESHOLD FOR RENAL PARENCHYMAL SPARING SURGERY. Journal of Urology, 1999, 161, 1475-1479.	0.2	229
144	MANAGEMENT OF HEREDITARY PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU KINDREDS WITH PARTIAL ADRENALECTOMY. Journal of Urology, 1999, 161, 395-398.	0.2	97

#	Article	IF	Citations
145	Automated bolus chase peripheral MR angiography: Initial practical experiences and future directions of this work-in-progress., 1999, 10, 376.		2
146	Clinical differentiation between proteus syndrome and hemihyperplasia: Description of a distinct form of hemihyperplasia., 1998, 79, 311-318.		97
147	Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Human Mutation, 1998, 12, 417-423.	1.1	452
148	From needles to numbers: can noninvasive imaging distinguish benign and malignant adrenal lesions?. World Journal of Urology, 1998, 16, 29-34.	1.2	15
149	PSEUDOTUMORS AFTER RENAL PARENCHYMAL SPARING SURGERY. Journal of Urology, 1998, 159, 1148-1151.	0.2	14
150	Improved detection of germline mutations in the von Hippelâ€Lindau disease tumor suppressor gene. Human Mutation, 1998, 12, 417-423.	1,1	38
151	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics, 1997, 16, 68-73.	9.4	1,461
152	Original Articles: Kidney Cancer: Parenchymal Sparing Surgery in Patients With Hereditary Renal Cell Carcinoma. Journal of Urology, 1995, 153, 913-916.	0.2	87
153	Original Articles: Kidney Cancer: Hereditary Papillary Renal Cell Carcinoma: Clinical Studies in 10 Families. Journal of Urology, 1995, 153, 907-912.	0.2	176
154	Hereditary Papillary Renal Cell Carcinoma. Journal of Urology, 1994, 151, 561-566.	0.2	289
155	Evaluation of Color Doppler Intraoperative Ultrasound in Parenchymal Sparing Renal Surgery. Journal of Urology, 1994, 152, 1984-1987.	0.2	44
156	Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. Cancer, 1993, 71, 1797-1800.	2.0	74
157	Dynamic Enhanced Magnetic Resonance Imaging of Testicular Perfusion in the Rat. Journal of Urology, 1993, 149, 1195-1197.	0.2	23
158	Regression of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy. Journal of Urology, 1993, 150, 463-466.	0.2	132
159	Intratesticular masses associated with abnormally functioning adrenal glands. Journal of Clinical Ultrasound, 1992, 20, 51-58.	0.4	22
160	A Report of Familial Carotid Body Tumors and Multiple Extra-Adrenal Pheochromocytomas. Journal of Urology, 1991, 145, 1040-1042.	0.2	31
161	With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer. Journal of Clinical Oncology, 0, , .	0.8	5